Clinical trial
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
NCT00053196 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00053196 |
|---|---|
| Title | Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer |
| Official title | Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myeloproliferative Neoplasms |
| Intervention type | Biological, Drug, Procedure |
| Interventions | anti-thymocyte globulin, G-CSF, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, allogeneic cell transplantation, allopurinol |
| Enrollment | 82 |
| Start date | Dec 1, 2002 |
| Primary completion | Nov 1, 2006 |
| Completion | Aug 1, 2010 |
| First posted | Jan 28, 2003 |
| Last update posted | Jul 1, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: